

Francesco Pezzella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7901785/publications.pdf>

Version: 2024-02-01

74
papers

6,234
citations

156536

32
h-index

100535

70
g-index

75
all docs

75
docs citations

75
times ranked

9992
citing authors

#	ARTICLE	IF	CITATIONS
1	Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies. <i>Cancer Reports</i> , 2022, 5, e1318.	0.6	24
2	On coalescent angiogenesis and the remarkable flexibility of blood vessels. <i>Angiogenesis</i> , 2022, 25, 1-3.	3.7	5
3	Vessel co-option and angiotropic extravascular migratory metastasis: a continuum of tumour growth and spread?. <i>British Journal of Cancer</i> , 2022, 126, 973-980.	2.9	7
4	Vascular Co-Option and Other Alternative Modalities of Growth of Tumor Vasculature in Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 874554.	1.3	10
5	Dissecting the heritable risk of breast cancer: From statistical methods to susceptibility genes. <i>Seminars in Cancer Biology</i> , 2021, 72, 175-184.	4.3	10
6	The Landscape of the Heritable Cancer Genome. <i>Cancer Research</i> , 2021, 81, 2588-2599.	0.4	13
7	Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 1680-1689.	2.9	37
8	Overview on the Different Patterns of Tumor Vascularization. <i>Cells</i> , 2021, 10, 639.	1.8	40
9	Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201. <i>PLoS ONE</i> , 2021, 16, e0249967.	1.1	1
10	The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer. <i>Cancers</i> , 2021, 13, 3433.	1.7	67
11	NUB1 and FAT10 Proteins as Potential Novel Biomarkers in Cancer: A Translational Perspective. <i>Cells</i> , 2021, 10, 2176.	1.8	5
12	Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis. <i>HemaSphere</i> , 2020, 4, e356.	1.2	4
13	Nonangiogenic tumor growth. , 2020, , 15-32.		1
14	Early squamous cell lung carcinoma: prognostic biomarkers for the many. <i>Thorax</i> , 2019, 74, 527-528.	2.7	3
15	Vessel co-option in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 469-493.	12.5	285
16	Pharmacogenetics implementation in the clinics: information and guidelines for germline variants. , 2019, 2, 595-607.		2
17	Non-angiogenic tumours and their influence on cancer biology. <i>Nature Reviews Cancer</i> , 2018, 18, 323-336.	12.8	113
18	The Role of JMY in p53 Regulation. <i>Cancers</i> , 2018, 10, 173.	1.7	14

#	ARTICLE	IF	CITATIONS
19	Association between hypoxic volume and underlying hypoxia-induced gene expression in oropharyngeal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2017, 116, 1057-1064.	2.9	20
20	Genomic insights of eeg strain patten in aortic stenosis: t wave inversion and st-segment depression are underlined by different molecular pathways. <i>Heart</i> , 2017, 103, A97.1-A97.	1.2	0
21	The convergence and divergence of molecular pathways in lv hypertrophy defined by eeg voltage versus lv mass in patients with aortic stenosis. <i>Heart</i> , 2017, 103, A98.1-A98.	1.2	0
22	Tumors and Blood Vessel Interactions: A Changing Hallmark of Cancer. , 2017, , 504-504.		0
23	Exosomes: recruits for tumour surveillance?. <i>Journal of Thoracic Disease</i> , 2017, 9, 4295-4299.	0.6	1
24	Evidence Showing That Tumors Can Grow Without Angiogenesis and Can Switch Between Angiogenic and Nonangiogenic Phenotypes. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw032.	3.0	11
25	Inhibition of NEDD8 and FAT10 ligase activities through the degrading enzyme NEDD8 ultimate buster 1: A potential anticancer approach. <i>Oncology Letters</i> , 2016, 12, 4287-4296.	0.8	2
26	Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1543-1557.	5.1	129
27	Why some tumours trigger neovascularisation and others don't: the story thus far. <i>Chinese Journal of Cancer</i> , 2016, 35, 18.	4.9	15
28	Twenty years after: the beautiful hypothesis and the ugly facts. <i>Chinese Journal of Cancer</i> , 2016, 35, 22.	4.9	7
29	Next-Generation Sequencing Analysis Reveals Differential Expression Profiles of MiRNA-mRNA Target Pairs in KSHV-Infected Cells. <i>PLoS ONE</i> , 2015, 10, e0126439.	1.1	19
30	Gene Signatures Stratify Computed Tomography Screening Detected Lung Cancer in High-Risk Populations. <i>EBioMedicine</i> , 2015, 2, 831-840.	2.7	7
31	Stromal CD8+ T-cell Density: A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2635-2643.	3.2	269
32	Non-angiogenic tumours unveil a new chapter in cancer biology. <i>Journal of Pathology</i> , 2015, 235, 381-383.	2.1	17
33	JMY protein, a regulator of P53 and cytoplasmic actin filaments, is expressed in normal and neoplastic tissues. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 715-722.	1.4	12
34	When Cancer Co-opts the Vasculature. <i>New England Journal of Medicine</i> , 2014, 370, 2146-2147.	13.9	4
35	TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC. <i>Molecular Cancer Research</i> , 2014, 12, 660-669.	1.5	59
36	Immunohistological recognition of cyclin D1 expression by non-lymphoid cells among lymphoid neoplastic cells. <i>Apmis</i> , 2014, 122, 183-191.	0.9	14

#	ARTICLE	IF	CITATIONS
37	Proline-Hydroxylated Hypoxia-Inducible Factor 1 \pm (HIF-1 \pm) Upregulation in Human Tumours. PLoS ONE, 2014, 9, e88955.	1.1	36
38	The diverse lives of TRAP1. Oncoscience, 2014, 1, 560-561.	0.9	1
39	Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 7967-78.	0.5	4
40	Overexpression of LC3A autophagy protein in follicular and diffuse large B-cell lymphomas. Hematology/ Oncology and Stem Cell Therapy, 2013, 6, 20-25.	0.6	13
41	Vessel co $\text{\r{e}}$ option in primary human tumors and metastases: an obstacle to effective anti $\text{\r{e}}$ angiogenic treatment?. Cancer Medicine, 2013, 2, 427-436.	1.3	231
42	<i>lgf2</i> pathway dependency of the <i>Trp53</i> developmental and tumour phenotypes. EMBO Molecular Medicine, 2012, 4, 705-718.	3.3	31
43	CD31 angiogenesis and combined expression of HIF-1 \pm and HIF-2 \pm are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIF \pm transcriptional products are not: implications for antiangiogenic trials and HIF \pm biomarker studies in primary CC-RCC. Carcinogenesis, 2012, 33, 1717-1725.	1.3	54
44	Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. Journal of Thoracic Disease, 2012, 4, 212-3.	0.6	16
45	Tumor necrosis factor receptor-associated protein 1 (TRAP1) regulates genes involved in cell cycle and metastases. Cancer Letters, 2010, 296, 194-205.	3.2	46
46	Atrial fibrillation is associated with cardiac hypoxia. Cardiovascular Pathology, 2010, 19, 102-111.	0.7	57
47	HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6532-6537.	3.3	141
48	Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. Journal of Cellular and Molecular Medicine, 2009, 13, 1248-1260.	1.6	154
49	Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis. Cancer Cell, 2009, 15, 57-66.	7.7	120
50	Nuclear and membrane expression of the angiogenesis regulator delta $\text{\r{e}}$ like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology, 2009, 54, 598-606.	1.6	16
51	Hypoxia and Myocardial Remodeling in Human Cardiac Allografts: A Time-course Study. Journal of Heart and Lung Transplantation, 2009, 28, 1119-1126.	0.3	36
52	Phosphorylated VEGFR2/KDR receptors are widely expressed in B $\text{\r{e}}$ cell non $\text{\r{e}}$ Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematological Oncology, 2008, 26, 219-224.	0.8	30
53	Detection of elevated levels of tumour $\text{\r{e}}$ associated microRNAs in serum of patients with diffuse large B $\text{\r{e}}$ cell lymphoma. British Journal of Haematology, 2008, 141, 672-675.	1.2	1,570
54	Different Growth Patterns of Non-Small Cell Lung Cancer Represent Distinct Biologic Subtypes. Annals of Thoracic Surgery, 2008, 85, 395-405.	0.7	37

#	ARTICLE	IF	CITATIONS
55	Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. <i>Cancer Letters</i> , 2008, 262, 87-93.	3.2	22
56	Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. <i>Leukemia and Lymphoma</i> , 2008, 49, 2181-2186.	0.6	18
57	Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 6634-6639.	3.2	84
58	BNIP3 as a Progression Marker in Primary Human Breast Cancer; Opposing Functions in In situ Versus Invasive Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 467-474.	3.2	81
59	Surveillance for the detection of early lung cancer in patients with bronchial dysplasia. <i>Thorax</i> , 2007, 62, 43-50.	2.7	98
60	Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2007, 8, 488-499.	5.1	68
61	Phosphorylated KDR can be located in the nucleus of neoplastic cells. <i>Cell Research</i> , 2006, 16, 93-98.	5.7	34
62	Expression of TRAIL and TRAIL receptors in normal and malignant tissues. <i>Cell Research</i> , 2005, 15, 430-438.	5.7	153
63	Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. <i>Oncogene</i> , 2005, 24, 1212-1219.	2.6	83
64	Somatic genetic changes accompanying lung tumor development. <i>Genes Chromosomes and Cancer</i> , 2005, 44, 65-75.	1.5	23
65	Lung Cancers Detected by Screening with Spiral Computed Tomography Have a Malignant Phenotype when Analyzed by cDNA Microarray. <i>Clinical Cancer Research</i> , 2004, 10, 6023-6028.	3.2	64
66	Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. <i>Molecular Cancer Research</i> , 2003, 1, 826-35.	1.5	84
67	Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. <i>Cancer Research</i> , 2002, 62, 1326-9.	0.4	156
68	Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. <i>Clinical Cancer Research</i> , 2002, 8, 2595-604.	3.2	237
69	bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. <i>British Journal of Cancer</i> , 1994, 69, 135-139.	2.9	301
70	bcl-2 Protein in Non-Small-Cell Lung Carcinoma. <i>New England Journal of Medicine</i> , 1993, 329, 690-694.	13.9	652
71	An Immunocytochemical Study of p53 and <i>bcl-2</i> Protein Expression in Hodgkin's Disease. <i>American Journal of Clinical Pathology</i> , 1993, 99, 663-667.	0.4	44
72	Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. <i>Cytometry</i> , 1992, 13, 502-509.	1.8	83

#	ARTICLE	IF	CITATIONS
73	The 14;18 translocation in European cases of follicular lymphoma: comparison of Southern blotting and the polymerase chain reaction. <i>British Journal of Haematology</i> , 1990, 76, 58-64.	1.2	109
74	HBV and HIV expression in lymph nodes of HIV positive LAS patients: histology and in situ hybridization. <i>Molecular and Cellular Probes</i> , 1989, 3, 125-132.	0.9	3